Streetbeat News

Products Services

VRAX

Virax Biolabs has initiated an early access program for the research-use-only of its proprietary SARS-Cov-2 ViraxImmune T-Cell-based test. This move could potentially increase the company's visibility in the biotech sector.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 11:39 am

MNMD

MindMed has completed the enrollment for its Phase 2b trial of MM-120, a drug aimed at treating Generalized Anxiety Disorder (GAD).

Portfolio Pulse from Bill Haddad

September 12, 2023 | 11:37 am

AAPL

AMZN

GOOG

MSFT

NVDA

QCOM

SFTBF

Arm Ltd is preparing for a significant initial public offering (IPO), with a strategic shift towards high-value chip design. The company's new focus includes mobile devices, cloud computing, automotive electronics, and IoT technology. Arm's CEO, Rene Haas, aims to increase the company's valuation to $54.5 billion in its IPO, a substantial increase from the $32 billion SoftBank Corp paid for Arm in 2016. The shift in strategy was prompted by Nvidia's failed attempt to purchase Arm for $40 billion in 2022.

Portfolio Pulse from Anusuya Lahiri

September 12, 2023 | 11:36 am

ARQT

Arcutis has submitted a Supplemental New Drug Application to the FDA for its Roflumilast Cream 0.15% for the treatment of atopic dermatitis in adults and children aged 6 years and older.

Portfolio Pulse from Bill Haddad

September 12, 2023 | 11:33 am

ALT

Altimmune has completed dosing in its Phase 2 MOMENTUM trial of Pemvidutide in subjects with obesity or overweight. This marks a significant milestone in the development of the drug.

Portfolio Pulse from Bill Haddad

September 12, 2023 | 11:33 am

NBIX

Neurocrine Biosciences has announced that its Phase 3 CAHtalyst Adult Study met its primary endpoint of a statistically significant decrease from baseline daily glucocorticoid dose with androgen control.

Portfolio Pulse from Bill Haddad

September 12, 2023 | 11:32 am

CRVL

CorVel Corporation has announced the release of its initial Generative AI module. This new technology is expected to enhance the company's capabilities in predictive analytics and decision-making processes.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 11:24 am

CVAC

GSK

CureVac is advancing its seasonal flu study to Phase 2 in collaboration with GSK. The trial, which is based on a promising mRNA vaccine candidate with broad coverage, is expected to start dosing in Q4 2023.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 11:20 am

CAMT

Camtek Ltd. (NASDAQ:CAMT) has announced that it has received orders for an additional 46 systems from several tier-1 High Bandwidth Memory (HBM) manufacturers since its last press release on August 29, 2023. The systems, which are critical for high performance computing in AI, gaming, and data centers, are expected to be delivered in 2024.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 11:18 am

DTIL

Precision Biosciences hosted a virtual R&D day, showcasing new preclinical data for its wholly-owned and partnered programs. The company also expanded its portfolio with PBGENE-PMM, a potential treatment for primary mitochondrial myopathy.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 11:16 am